CN1850817A - Roofirisrhizome flavin non polar isostere, and its preparing method and use - Google Patents
Roofirisrhizome flavin non polar isostere, and its preparing method and use Download PDFInfo
- Publication number
- CN1850817A CN1850817A CN200610040665.0A CN200610040665A CN1850817A CN 1850817 A CN1850817 A CN 1850817A CN 200610040665 A CN200610040665 A CN 200610040665A CN 1850817 A CN1850817 A CN 1850817A
- Authority
- CN
- China
- Prior art keywords
- methyl
- cho
- calc
- kbr
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title claims description 19
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- -1 NR 2 Inorganic materials 0.000 claims description 82
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 claims description 34
- OTKCEEWUXHVZQI-UHFFFAOYSA-N 1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(=O)CC1=CC=CC=C1 OTKCEEWUXHVZQI-UHFFFAOYSA-N 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 claims description 17
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000010792 warming Methods 0.000 claims description 14
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 6
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 6
- 235000008696 isoflavones Nutrition 0.000 claims description 6
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical class C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229960001866 silicon dioxide Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- 230000000452 restraining effect Effects 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- CNOURESJATUGPN-UDEBZQQRSA-N tectoridin Chemical compound C1=C2OC=C(C=3C=CC(O)=CC=3)C(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNOURESJATUGPN-UDEBZQQRSA-N 0.000 abstract 1
- FHFSSMDJUNVMNY-UHFFFAOYSA-N tectoridin Natural products COc1c(O)c2C(=O)C(=COc2cc1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 FHFSSMDJUNVMNY-UHFFFAOYSA-N 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 104
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 103
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000000967 suction filtration Methods 0.000 description 12
- 238000013019 agitation Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000005406 washing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- GHWMJHVRRWGBMD-UHFFFAOYSA-N 3-bromo-2-phenyl-3H-quinolin-4-one Chemical compound BrC1C(=O)C2=CC=CC=C2N=C1C1=CC=CC=C1 GHWMJHVRRWGBMD-UHFFFAOYSA-N 0.000 description 4
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 4
- 241000596154 Belamcanda Species 0.000 description 4
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 description 4
- 101800001026 Irisin Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- AYKYOOPFBCOXSL-UHFFFAOYSA-N (4-hydroxyphenyl)acetonitrile Chemical compound OC1=CC=C(CC#N)C=C1 AYKYOOPFBCOXSL-UHFFFAOYSA-N 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- NRPFNQUDKRYCNX-UHFFFAOYSA-N 4-methoxyphenylacetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- DOCCDOCIYYDLGJ-UHFFFAOYSA-N ethyl 2-(4-methoxyphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(OC)C=C1 DOCCDOCIYYDLGJ-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- HKHXLHGVIHQKMK-UHFFFAOYSA-N 2-chloro-m-cresol Chemical compound CC1=CC=CC(O)=C1Cl HKHXLHGVIHQKMK-UHFFFAOYSA-N 0.000 description 1
- NUNAWQZKZVVELQ-UHFFFAOYSA-N 3-amino-4-methylphenol Chemical compound CC1=CC=C(O)C=C1N NUNAWQZKZVVELQ-UHFFFAOYSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- VQZRLBWPEHFGCD-UHFFFAOYSA-N 3-chloro-4-methylphenol Chemical compound CC1=CC=C(O)C=C1Cl VQZRLBWPEHFGCD-UHFFFAOYSA-N 0.000 description 1
- QIORDSKCCHRSSD-UHFFFAOYSA-N 3-methyl-2-nitrophenol Chemical class CC1=CC=CC(O)=C1[N+]([O-])=O QIORDSKCCHRSSD-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to tectoridin digital isostere, they has following constitutional general formula, X is oxygen or NH. It has restraining effect ot cancer cell, and can be used to prepare anti tumor medicine, this invention also discloses its preparation method.
Description
Technical field
The present invention relates to isostere and method for making and their application in the preparation antitumor drug of a class tectorigenin.
Technical background
Tectorigenin is the main active ingredient of Chinese medicinal materials blackberry lily, has following structure:
Blackberry lily is the dry rhizome of Iridaceae blackberry lily platymiscium blackberry lily [Belamcanda chinensis (L.) DC], has effect clearing heat and detoxicating, the relieve sore throat dissolving phlegm, is mainly used in diseases such as throat lung carbuncle, productive cough asthma, is the key medicine of treatment larynx numbness pharyngalgia.Because tectorigenin has estrogen-like effects, thereby when tectorigenin and oestrogenic hormon acted on target organ simultaneously, the two competed conjugated estrogen hormone acceptor, thereby alleviates estrogenic short cel l proliferation, reduces the pathogenesis of cancer danger relevant with oestrogenic hormon.Simultaneously tectorigenin also has to a certain degree restraining effect to non-estrogen-dependent tumour, as tectorigenin HL-60 cell (leukemia cell) is had very strong restraining effect.Tectorigenin also has to a certain degree restraining effect to the propagation of BGC cell (adenocarcinoma of stomach).
The experimentation on animals of Thelen P et al. shows that tectorigenin has the effect of obvious suppression tumour, finds that it can be used as the medicine of prevention and treatment people's prostate cancer.Saratikov; A.S.et al. studies show that; polyols such as tectorigenin can suppress hepatocellular necrosis; stop intrahepatic fat and proteinic unbalance; make the active normalizing of transaminase and glutamyl transferring enzyme; prevented the development of hepatic fibrosis, the effect that play the protection liver, recovers liver function.Act on the liver cell of mouse with tertbutyl peroxide, take tectorigenin then, find that tectorigenin can protect mouse to avoid the infringement of tertbutyl peroxide inductive liver cancer cell.Intracellular active oxygen is one of factor that causes cell carcinogenesis, tectorigenin can be removed active oxygen on the one hand, can increase the active of superoxide dismutase, catalase and glutathione peroxidase and their protein level on the other hand, strengthen the ability of cell removing active oxygen.Tectorigenin also has the effect of fine anti-hepatic fibrosis.
Summary of the invention
The objective of the invention is to the tectorigenin is guide's thing, the isostere that synthesizes a series of tectorigenins by some ultimate principles of medicinal design, on the basis of further investigation structure activity relationship, find the new drug that activity is higher, toxic side effect is lower, and the method for making of Roofirisrhizome flavin non polar isostere is provided.
Technical scheme of the present invention is as follows:
The isostere of one class tectorigenin, they have following general structure:
Among the formula II, when X is O (compound III: replace isoflavones):
R
1=H, R
2=R, R
3=CHO and R
4=OR, then R
5=R, NO
2, CHO, CN, NR
2, F or CH
2OH;
R
1=H, R
2=R, R
3=CN and R
4=OR, then R
5=R, NO
2, CHO or CN;
R
1=H, R
2=R, R
3=NO
2And R
4=OR, then R
5=NO
2, CHO or CN
R
1=H, R
2=R, R
3=CH
2OH and R
4=OR, then R
5=R, NO
2, NR
2, Cl, Br, CHO, CH
2OH or CN;
R
1=H, R
2=R, R
3=NR
2And R
4=OR, then R
5=R;
R
1=H, R
2=R, R
3=Cl and R
4=OR, then R
5=R, CHO or CN;
R
1=H, R
2=R, R
3=Br and R
4=OR, then R
5=R, CH
2OH or CN;
R
1=H, R
2=R, R
3=F and R
4=OH, then R
5=R, CH
2OH or CN;
R
1=CHO, R
2=R, R
3=R and R
4=OR, then R
5=R, NO
2, CHO, CN, NR
2, F or CH
2OH;
R
1=CN, R
2=R, R
3=R and R
4=OR, then R
5=R, NO
2, CHO or CN;
R
1=NO
2, R
2=R, R
3=R and R
4=OR, then R
5=NO
2, CHO or CN;
R
1=CH
2OH, R
2=R, R
3=R and R
4=OR, then R
5=H, NO
2, NR
2, CHO, Cl, Br, CH
2OH or CN;
R
1=NR
2, R
2=R, R
3=R and R
4=OR, then R
5=R;
R
1=Cl, R
2=R, R
3=R and R
4=OR, then R
5=R, CHO or CN;
R
1=Br, R
2=R, R
3=R and R
4=OR, then R
5=R, CH
2OH or CN;
R
1=F, R
2=R, R
3=R and R
4=OR, then R
5=R, CH
2OH or CN;
Described R=H, CH
3Or C
2H
5
Among the formula II, when X is NH (compound V: replacement-4-quinolinone):
R
1And R
3=Br, R
2=OR and R
5=R, then R
4=NO
2, NR
2, F, Cl, Br or OCH
3
R
1And R
3=H, R
2=OR or OCH
3And R
4=OR, then R
5=NO
2, NR
2, F, Cl or Br;
Described R=H, CH
3Or C
2H
5
A kind of method for preparing Roofirisrhizome flavin non polar isostere replacement isoflavones (compound III), it is made up of the following step basically:
Step 1. is with 4-methyl-3-R
3-5-R
1-phenol and 4-hydroxyl-3-R
5-benzyl cyanide is dissolved in anhydrous Et
2(the ratio of amount of substance: 4-methyl-3-R among the O
3-5-R
1-phenol: 4-hydroxyl-3-R
5-benzyl cyanide=1: 1), ice bath and stirring feed exsiccant HCl gas down, and reaction 24h obtains 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone and 3-methyl-2-R
1-4-R
3-6,4 '-dihydroxyl phenylbenzyl ketone,
Step 2. is with 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone and 3-methyl-2-R
1-4-R
3-6,4 '-dihydroxyl phenylbenzyl ketone carries out column chromatography by silicagel column, isolates 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone,
Step 3. is with 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone is dissolved in the dry DMF, slowly drips BF
3Et
2O is warming up to 40~60 ℃, splashes into CH
3SO
2The DMF solution of Cl, the ratio of the amount of substance of three materials is: 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone: BF
3Et
2O: CH
3SO
2Cl=1: 3: 2~1: 10: 6, be warming up to 60~90 ℃, reaction 1h generates the Roofirisrhizome flavin non polar isostere compound III:
A kind of method for preparing Roofirisrhizome flavin non polar isostere substituted 4-quinolinone (compound V), it is made up of the following step basically:
Step 1. is with 3-R
3-4-R
2-5-R
1-aniline is dissolved in the dehydrated alcohol, adds 2-(4 '-R
4-3 '-R
5-phenyl)-and the formyl radical ethyl acetate, 3-R
3-4-R
2-5-R
1-aniline and 2-(4 '-R
4-3 '-R
5-phenyl)-ratio of the amount of substance of formyl radical ethyl acetate is: 3-R
3-4-R
2-5-R
1-aniline: 2-(4 '-R
4-3 '-R
5-phenyl)-and the formyl radical ethyl acetate=1: 1~1: 2, at room temperature stir 5~24h, get compound IV:
Step 2. is heated to the compound IV that step 1 obtains between 80~150 ℃ in the presence of polyphosphoric acid (PPA), obtains substituted 4-quinolinone (compound V):
Experiment showed, that Roofirisrhizome flavin non polar isostere has restraining effect to S180, EAC and HepA cell, 5 kinds of human cancer cells are had restraining effect, so they can be used to prepare anti-tumor drug.
Embodiment
Further describe the present invention by following examples, but should notice that scope of the present invention is not subjected to any restriction of these embodiment.
The preparation of embodiment 1:6-methyl-5-nitro-4 '-hydroxy-isoflavone (15) and 6-methyl-7-nitro-4 '-hydroxy-isoflavone (16)
A5-methyl-4-nitro-2,4 '-dihydroxyl phenylbenzyl ketone and 3-methyl-2-nitro-6, the preparation of 4 '-dihydroxyl phenylbenzyl ketone
300mg 3-methyl-2-nitrophenols in the 50mL there-necked flask, is added the 8mL anhydrous diethyl ether, the 266mg p-hydroxybenzylcyanide, dissolving feeds exsiccant HCl under the ice bath cooling, reaction 24h, have faint yellow solid to separate out, suction filtration is with a small amount of ether washing solid, be transferred in the round-bottomed flask, add 5mL water, reflux 1h, in heat-processed, precipitation is dissolving slowly, occurs precipitation then again, filter, get a light-yellow precipitate, cross silicagel column and get two components:
5-methyl-4-nitro-2,4 '-dihydroxyl phenylbenzyl ketone (246mg), yield 43%.Mp 227-228℃;ESI-MS:287.0820(calc.287.0815);IR(KBr)cm
-1:1675(C=O),3585(OH);
1H NMR(DMSO-d
6)δppm:2.64(s,3H),4.14(s,2H),6.61(d,2H),6.89(d,2H),7.65(s,1H),7.75(s,1H),9.83(s,1H),10.51(s,1H)。3-methyl-2-nitro-6,4 '-dihydroxyl phenylbenzyl ketone (172mg), yield 30%.Mp 218-219℃;ESI-MS:287.0817(calc.287.0815);IR(KBr)cm
-1:1675(C=O),3585(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),4.14(s,2H),6.61(d,2H),6.89(d,2H),7.11(d,1H),7.34(d,1H),9.81(s,1H),10.54(s,1H)。
The preparation of B 6-methyl-5-nitro-4 '-hydroxy-isoflavone
With 287mg 3-methyl-2-nitro-6,4 '-dihydroxyl phenylbenzyl ketone is dissolved in the 1.8mL dry DMF, drips BF under magnetic agitation and water-bath
3Et
2O 0.5mL is warming up between 50-60 ℃, drips 0.4mL CH
3SO
2The solution of Cl in 0.9mLDMF is warming up to 90 ℃ of reaction 2.5h then, and cooling is poured in the aqueous solution of AcONa, spends the night, and suction filtration washes twice with water, dried 198.3mg khaki color solid, productive rate 69%, Mp 235-237 ℃; ESI-MS:297.0640 (calc.297.0633); IR (KBr) cm
-1: 1675 (C=O), 3595 (OH);
1HNMR (DMSO-d
6) δ ppm:2.33 (s, 3H), 6.68 (d, 2H), 7.43 (d, 1H), 7.46 (d, 2H), 8.00 (d, 1H), 8.15 (s, 1H), 9.78 (s, 1H).
The preparation of C 6-methyl-7-nitro-4 '-hydroxy-isoflavone
With 287mg 5-methyl-4-nitro-2,4 '-dihydroxyl phenylbenzyl ketone is dissolved in the 1.8mL dry DMF, drips BF under magnetic agitation and water-bath
3Et
2O 0.5mL is warming up between 50-60 ℃, drips 0.4mL CH
3SO
2The solution of Cl in 0.9mLDMF is warming up to 90 ℃ of reaction 2.5h then, and cooling is poured in the aqueous solution of AcONa, spends the night, and suction filtration washes twice with water, dried 216.8mg khaki color solid, productive rate 73%.Mp 238-240℃;ESI-MS:297.0639(calc.297.0633);IR(KBr)cm
-1:1676(C=O),3589(OH);
1HNMR(DMSO-d
6)δppm:2.64(s,3H),6.68(d,2H),7.46(d,2H),7.70(s,1H),7.73(s,1H),8.20(s,1H),9.83(s,1H)。
Embodiment 2
Pressing embodiment 1 similar methods, is raw material with different fortified phenols, has synthesized the listed Roofirisrhizome flavin non polar isostere 1~22 of table 1.
Each R group of Roofirisrhizome flavin non polar isostere in table 1 general formula III
Sequence number | R 1 | R 2 | R 3 | R 4 | R 5 |
1 | H | CH 3 | CHO | OH | H |
2 | CHO | CH 3 | H | OH | H |
3 | H | CH 3 | CN | OH | H |
4 | CN | CH 3 | H | OH | H |
5 | H | CH 3 | CHO | OH | NO 2 |
6 | CHO | CH 3 | H | OH | NO 2 |
7 | H | CH 3 | CN | OH | NO 2 |
8 | CN | CH 3 | H | OH | NO 2 |
9 | H | CH 3 | NO 2 | OH | NO 2 |
10 | NO 2 | CH 3 | H | OH | NO 2 |
11 | H | CH 3 | CHO | OH | CHO |
12 | CHO | CH 3 | H | OH | CHO |
13 | H | CH 3 | CN | OH | CHO |
14 | CN | CH 3 | H | OH | CHO |
15 | H | CH 3 | NO 2 | OH | CHO |
16 | NO 2 | CH 3 | H | OH | CHO |
17 | H | CH 3 | CHO | OH | CN |
18 | CHO | CH 3 | H | OH | CN |
19 | H | CH 3 | CN | OH | CN |
20 | CN | CH 3 | H | OH | CN |
21 | H | CH 3 | NO 2 | OH | CN |
22 | NO 2 | CH 3 | H | OH | CN |
Annotate: initial feed is all available from aldrich company
The preparation of embodiment 3:6-methyl-7-amino-4 '-hydroxy-isoflavone (26)
297mg6-methyl-7-nitro-4 '-hydroxy-isoflavone is dissolved in the 5mL methyl alcohol, adds 24mg10%Pd-C, feed hydrogen,, filter, boil off methyl alcohol, get a faint yellow solid, heavy 254mg, productive rate 95% under agitation in room temperature reaction 15h.Mp 212-214℃;ESI-MS:297.00931(calc.267.0928);IR(KBr)cm
-1:1676(C=O),3490(NH),3547(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),5.85(s,2H),6.01(s,1H),6.67(d,2H),7.19(s,1H),7.46(d,2H),8.33(s,1H),9.76(s,1H)。
The preparation of embodiment 4:6-methyl-7-methylol-4 '-hydroxy-isoflavone (24)
280mg6-methyl-7-formyl radical-4 '-hydroxy-isoflavone is dissolved among the anhydrous THF of 3mL, places constant pressure funnel, 100mgLiAlH
4In there-necked flask, the anhydrous THF of adding 4mL under stirring and ice bath cooling, drips in the solution of above-mentioned isoflavones, drips off the back and react 1h under 25-30 ℃, carefully splashes into the saturated NH of 2mL then under the ice bath cooling
4Cl solution, suction filtration washs solid with THF, gets white solid 265mg, productive rate 94% after filtrate concentrates.Mp219-221℃;ESI-MS:282.0909(calc.282.0904);IR(KBr)cm
-1:1676(C=O),3547(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),4.79(d,2H),5.39(t,1H),6.66(d,2H),6.73(s,1H),7.37(s,1H),8.29(s,1H),9.80(s,1H)。
The system of embodiment 5:6-methyl-5-chloro-4 '-hydroxy-isoflavone (27) respectively
The preparation of A 4-methyl-3-amino-phenol
612mg4-methyl-3-nitro phenol is dissolved in the 15mL methyl alcohol, adds 96mg10%Pd-C, feed hydrogen,, filter, boil off methyl alcohol, get a white solid, heavy 472mg, productive rate 96% under agitation in room temperature reaction 15h.Mp 113-115℃;ESI-MS:123.0705(calc.123.0711);IR(KBr)cm
-1:3493(NH),3552(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),5.81(d,1H),5.85(s,2H),5.97(d×d,1H),6.64(d,1H),8.01(s,1H)。
The preparation of B 4-methyl-3-chlorophenol
2mL concentrated hydrochloric acid and isopyknic water are poured into round-bottomed flask, under magnetic agitation, add 1.42g4-methyl-3-amino-phenol, be cooled to 0 ℃, add 0.7gNaNO
2The aqueous solution, in the adition process, keep system temperature to be no more than 5 ℃, add CuCl0.99g, be warming up to 50 ℃ gradually, crystal is separated out in cooling, suction filtration, drying, product 0.95g, productive rate 67%.Mp 121-123℃;ESI-MS:142.0230(calc.142.0234);IR(KBr)cm
-1:3552(OH);
1H NMR(DMSO-d
6)δppm:2.37(s,3H),6.49(d×d,1H),6.62(d,1H),6.83(d,1H),8.20(s,1H)。
C 5-methyl-4-chloro-2,4 '-dihydroxyl phenylbenzyl ketone and 3-methyl-2-chloro-6, the preparation of 4 '-dihydroxyl phenylbenzyl ketone
284mg 3-methyl-2-chlorophenol in the 50mL there-necked flask, is added the 8mL anhydrous diethyl ether, the 266mg p-hydroxybenzylcyanide, dissolving feeds exsiccant HCl under the ice bath cooling, reaction 24h, have faint yellow solid to separate out, suction filtration is with a small amount of ether washing solid, be transferred in the round-bottomed flask, add 5mL water, reflux 1h, in heat-processed, precipitation is dissolving slowly, occurs precipitation then again, filter, get a light-yellow precipitate, cross silicagel column and get two components:
5-methyl-4-chloro-2,4 '-dihydroxyl phenylbenzyl ketone (210mg), yield 38%.Mp 216-217℃;ESI-MS:276.0629(calc.276.0631);IR(KBr)cm
-1:1675(C=O),3585(OH);
1H NMR(DMSO-d
6)δppm:2.64(s,3H),4.16(s,2H),6.63(d,2H),6.73(s,1H),6.85(d,2H),7.43(s,1H),9.83(s,1H),11.29(s,1H)。3-methyl-2-chloro-6,4 '-dihydroxyl phenylbenzyl ketone (177mg), yield 32%.Mp 209-211℃;ESI-MS:276.0633(calc.276.0631);IR(KBr)cm
-1:1675(C=O),3585(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),4.12(s,2H),6.60(d,1H),6.63(d,2H),6.70(d,2H),7.02(d,1H),9.84(s,1H),11.36(s,1H)。
The preparation of D 6-methyl-5-chloro-4 '-hydroxy-isoflavone
With 276mg 3-methyl-2-chloro-6,4 '-dihydroxyl phenylbenzyl ketone is dissolved in the 1.8mL dry DMF, drips BF under magnetic agitation and water-bath
3Et
2O 0.5mL is warming up between 50-60 ℃, drips 0.4mL CH
3SO
2The solution of Cl in 0.9mLDMF is warming up to 90 ℃ of reaction 2.5h then, and cooling is poured in the aqueous solution of AcONa, spends the night, and suction filtration washes twice with water, dried 213mg khaki color solid, productive rate 77%.Mp 229-230℃;ESI-MS:286.0422(calc.286.0418);IR(KBr)cm
-1:1677(C=O),3587(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),6.64(d,2H),7.11(d,1H),7.46(d,2H),7.49(d,1H),8.21(s,1H),9.85(s,1H)。
Embodiment 6:
By above embodiment similar methods,, synthesized the listed Roofirisrhizome flavin non polar isostere 23~64 of table 2 with different fortified phenols.
Each R group of Roofirisrhizome flavin non polar isostere in table 2 general formula III
Sequence number | R 1 | R 2 | R 3 | R 4 | R 5 1 |
23 | H | CH 3 | CH 2OH | OH | H |
24 | CH 2OH | CH 3 | H | OH | H |
25 | H | CH 3 | NH 2 | OH | H |
26 | NH 2 | CH 3 | H | OH | H |
27 | H | CH 3 | Cl | OH | H |
28 | Cl | CH 3 | H | OH | H |
29 | H | CH 3 | Br | OH | H |
30 | Br | CH 3 | H | OH | H |
31 | H | CH 3 | F | OH | H |
32 | F | CH 3 | H | OH | H |
33 | H | CH 3 | CHO | OH | NH 2 |
34 | CHO | CH 3 | H | OH | NH 2 |
35 | H | CH 3 | CH 2OH | OH | NO 2 |
36 | CH 2OH | CH 3 | H | OH | NO 2 |
37 | H | CH 3 | CH 2OH | OH | NH 2 |
38 | CH 2OH | CH 3 | H | OH | NH 2 |
39 | H | CH 3 | CHO | OH | F |
40 | CHO | CH 3 | H | OH | F |
41 | H | CH 3 | CH 2OH | OH | Cl |
42 | CH 2OH | CH 3 | H | OH | Cl |
43 | H | CH 3 | CH 2OH | OH | Br |
44 | CH 2OH | CH 3 | H | OH | Br |
45 | H | CH 3 | CHO | OH | CH 2OH |
46 | CHO | CH 3 | H | OH | CH 2OH |
47 | H | CH 3 | CH 2OH | OH | CHO |
48 | CH 2OH | CH 3 | H | OH | CHO |
49 | H | CH 3 | CH 2OH | OH | CH 2OH |
50 | CH 2OH | CH 3 | H | OH | CH 2OH |
51 | H | CH 3 | F | OH | CH 2OH |
52 | F | CH 3 | H | OH | CH 2OH |
53 | H | CH 3 | Cl | OH | CHO |
54 | Cl | CH 3 | H | OH | CHO |
55 | H | CH 3 | Br | OH | CH 2OH |
56 | Br | CH 3 | H | OH | CH 2OH |
57 | H | CH 3 | CH 2OH | OH | CN |
58 | CH 2OH | CH 3 | H | OH | CN |
59 | H | CH 3 | F | OH | CN |
60 | F | CH 3 | H | OH | CN |
61 | H | CH 3 | Cl | OH | CN |
62 | Cl | CH 3 | H | OH | CN |
63 | H | CH 3 | Br | OH | CN |
64 | Br | CH 3 | H | OH | CN |
Annotate: raw material gets the material of order in table 1
Embodiment 7:5, the preparation of 7-two bromo-6-hydroxyl-3-(p-methoxyphenyl)-4-quinolinone (65)
The preparation of A homoanisic acid
5.6gKOH is dissolved in the 37mL water, under magnetic agitation, adds p-hydroxyphenylaceticacid 3.4g, splash into 5.3mL (MeO) 40 ℃ of left and right sides gradation
2SO
2(approximately dripping 2mL every 2h) reacted down at 45 ℃ then and spent the night (12h), and cooling is filtered by diatomite layer, and the filtrate concentrated hydrochloric acid is transferred between pH to 2-3, cooling, and suction filtration, with a spot of water washing once, drying gets white crystalline solid 3.6g, productive rate 96%.Mp 115-117℃;ESI-MS:166.0629(calc.166.0629);IR(KBr)cm
-1:1680(C=O),3604(OH);
1H NMR(DMSO-d
6)δppm:3.72(s,3H),6.86(d,2H),7.16(d,2H),12.25(s,1H)。
The preparation of B homoanisic acid ethyl ester
The 1.5g homoanisic acid is dissolved in the 6mL ethanol, splashes into 0.5mL H
2SO
4, temperature rising reflux 22h, cooling with the 100mLAcOEt extraction, is used Na successively
2CO
3Solution, saturated common salt water washing, anhydrous MgSO
4Drying boils off solvent and gets weak yellow liquid 1.6g, productive rate 90%.ESI-MS:194.0947(calc.194.0942);IR(KBr)cm
-1:1678(C=O);
1H NMR(CDCl3)δppm:1.25(t,3H),4.14(q,2H),6.86(d,2H),720(d,2H)。
The preparation of C 2-(p-methoxyphenyl)-2-formyl radical ethyl acetate
1.6g homoanisic acid ethyl ester is dissolved in 14mL HCO
2Among the Et, at N
2Add 0.86g NaH under stream protection and the magnetic agitation in batches, after adding, at room temperature react 1h, reaction solution is poured into 30mL through among rare HCl of refrigerated 5%, use Et
2Saturated NaHCO is used in the O extraction successively
3With saturated salt solution washing, use anhydrous MgSO
4Drying boils off solvent, spends the night in 40 ℃ of following vacuum-dryings, gets weak yellow liquid 1.8g, productive rate 90%.ESI-MS:222.0886(calc.222.0892);IR(KBr)cm
-1:1680(C=N),3410(OH);
1H NMR(CDCl
3)δppm:1.28(t,3H),3.82(s,3H),4.29(q,2H),6.88(d,2H),7.19(d,2H),7.25(d,1H),12.05(d,1H)。
D 2, the preparation of 6-two bromo-4-nitrophenolss
The 2.78g p-NP is joined in the there-necked flask of 100mL, add 8.3mLAcOH, allow its dissolving, at room temperature in 3h, drip the solution (about per minute one droplet) of 2.4mL bromine (7.5g) in 7mLAcOH, drip off the back, be warming up to 100 ℃ continuing reaction 1.5h, blast air, driving away excessive bromine (absorbing bromine with an alkali cleaning gas cylinder), is faint yellow until solution, adds 11mL water, cooling, separate out crystal, suction filtration, the AcOH solution washing with 50% is once, the dilute hydrochloric acid washing once, drying gets faint yellow solid 5.1g, productive rate 86%.Mp 98-100℃;ESI-MS:294.8481(calc.294.8479);IR(KBr)cm
-1:3485(OH);
1H NMR(DMSO-d
6)δppm:6.52(s,1H),8.41(s,2H)。
E 3, the preparation of 5-two bromo-4-hydroxyl puratized agricultural spray chlordene stannates
With 1.48g 2,6-two bromo-4-nitrophenolss join in the there-necked flask of 100mL, add 6mL (1: 1) hydrochloric acid, under agitation are heated to 60 ℃, 1.9g Sn is added in batches, add 16mL dilute hydrochloric acid (10mL concentrated hydrochloric acid+6mL water) altogether in this process frequently, heating (90 ℃) is to solid 2, and 6-two bromo-4-nitrophenolss disappear, with funnel suction filtration through preheating, cooling is separated out crystal, 2.14g, productive rate 98.6%.5.6gKOH is dissolved in the 37mL water, under magnetic agitation, adds p-hydroxyphenylaceticacid 3.4g, splash into 5.3mL (MeO) 40 ℃ of left and right sides gradation
2SO
2(approximately dripping 2mL every 2h) reacted down at 45 ℃ then and spent the night (12h), and cooling is filtered by diatomite layer, and filtrate is transferred between pH to 2-3 with concentrated hydrochloric acid, cooling, and suction filtration, with a spot of water washing once, drying gets white crystalline solid 3.6g, productive rate 96%.Mp 125-127℃;ESI-MS:867.4790(calc.867.4785);IR(KBr)cm
-1:3477(OH);
1H NMR(DMSO-d
6)δppm-7.38(s,2H),9.85(s,3H)。
F 3-[N-(3,5-two bromo-4-hydroxy phenyls) amino]-preparation of 2-(p-methoxyphenyl) ethyl propenoate
Rare HCl of 40mL8% is joined in the flask, under magnetic agitation, add 2.17g 3,5-two bromo-4-hydroxyl puratized agricultural spray chlordene stannates; be warming up to 90 ℃; after waiting to dissolve, splash into 1.03g 2-p-methoxyphenyl-2-formyl radical ethyl acetate, generate yellow mercury oxide immediately; continue reaction 2h; suction filtration is with a small amount of EtOH washing three times, vacuum-drying; get faint yellow solid 1.7g, productive rate 79%.Mp 189-191℃;ESI-MS:468.9519(calc.468.9524);IR(KBr)cm
-1:1600(C=C),1708(C=O),3458(NH,OH);
1H NMR(DMSO-d
6)δppm:1.19(t,3H),3.75(s,3H),4.16(q,2H),6.86(d,2H),7.26(d,2H),7.49(d,1H),7.60(s,2H),9.51(s,1H),10.4(d,1H)。
G 5, the preparation of 7-two bromo-6-hydroxyl-3-(p-methoxyphenyl)-4-quinolinones
Get the 15g phenyl ether in there-necked flask, add 500mg 3-[N-(3,5-two bromo-4-hydroxy phenyls) amino]-2-p-methoxyphenyl ethyl propenoate, be warming up to 250 ℃ of reaction 10min, cooling adds the 20mL sherwood oil, separate out precipitation, filter, vacuum-drying gets faint yellow solid 250mg, productive rate 55%.Mp 225-227℃;ESI-MS:422.9110(calc.422.9105);IR(KBr)cm
-1:1600(C=C),1708(C=O),3458(NH,OH);
1HNMR(DMSO-d
6)δppm:3.77(s,3H),6.93(d,2H),7.57(d,2H),7.83(s,1H),8.00(d,1H),9.69(s,1H),11.85(d,1H)。
Embodiment 8:
We have synthesized the isostere 65~86 of the listed tectorigenin of table 3 by above embodiment similar methods.
Embodiment 9: Roofirisrhizome flavin non polar isostere is to S180, EAC, the cytotoxicity of HepA
Method: mtt assay.The S180 that takes the logarithm and grow, the cell of EAC and HepA is diluted to 2 * 10 respectively
4Individual/ml, be sub-packed in 96 orifice plates (0.2ml/ hole).If the 5 FU 5 fluorouracil control group, the tested compounds of DMSO control group and 8 different concns, every hole 10 μ l.Each group is established 4 parallel holes, puts 37 ℃, 5%CO
24h squeezed into MTT liquid (5mg/ml) 10 μ l/ holes before the middle 72h of cultivation experiment stopped, and cultivated 4h again.Discard nutrient solution, add DMSO 100 μ l/ holes, the mixing vibration under the 570nm wavelength, is measured the OD value with BioRad produced in USA 550 type microplate reader, calculates inhibitory rate of cell growth (half-inhibition concentration, IC by following formula
50).
Growth inhibition ratio=(the average OD value of the average OD value/control group of 1-medication group) * 100%
IC
50More little, the cytotoxicity of this compound is big more, the results are shown in Table 4.
The result shows: the series electronic isostere of main irisin of the present invention is to S180, EAC and HepA cell demonstrate more intense cytotoxicity, most of suitable with the positive control 5 FU 5 fluorouracil, wherein, the cytotoxicity of 74 pairs of S180 cells of compound, 50 pairs of EAC cells of compound, 65 pairs of HepA cells of compound even also being eager to excel than 5 FU 5 fluorouracil.
Embodiment 10: Roofirisrhizome flavin non polar isostere is to the restraining effect of 5 kinds of human cancer cells
Method: mtt assay.Experimental technique the results are shown in Table 5 with embodiment 9.
Each R group of Roofirisrhizome flavin non polar isostere in table 3 general formula III
Sequence number | R 1 | R 2 | R 3 | R 4 | R 5 |
65 | Br | OH | Br | OCH 3 | H |
66 | Br | OCH 3 | Br | OCH 3 | H |
67 | Br | OH | Br | NO 2 | H |
68 | Br | OCH 3 | Br | NO 2 | H |
69 | Br | OH | Br | NH 2 | H |
70 | Br | OCH 3 | Br | NH 2 | H |
71 | Br | OH | Br | F | H |
72 | Br | OCH 3 | Br | F | H |
73 | Br | OH | Br | Cl | H |
74 | Br | OCH 3 | Br | Cl | H |
75 | Br | OH | Br | Br | H |
76 | Br | OCH 3 | Br | Br | H |
77 | H | OH | H | OH | NO 2 |
78 | H | OCH 3 | H | OH | NO 2 |
79 | H | OH | H | OH | NH 2 |
80 | H | OCH 3 | H | OH | NH 2 |
81 | H | OH | H | OH | F |
82 | H | OCH 3 | H | OH | F |
83 | H | OH | H | OH | Cl |
84 | H | OCH 3 | H | OH | Cl |
85 | H | OH | H | OH | Br |
86 | H | OCH 3 | H | OH | Br |
Annotate: initial feed is all available from aldrich company
The series electronic isostere of table 4 irisin is to S180, the cytotoxicity (IC of EAC and HepA
50)
Cell strain | Compound number/IC 50(μg/ml) | ||||||
1 | 25 | 50 | 65 | 74 | 83 | 5 FU 5 fluorouracil | |
S180 EAC HepA | 4.84 10.28 2.39 | 25 43 8.78 | 21.84 0.21 2.54 | 17 47 1.23 | 023 3.82 2.55 | 4.76 24 13 | 1.32 0.26 1.87 |
The series electronic isostere of table 5. irisin is to the restraining effect of 5 kinds of human cancer cells
Group | Drug level (μ g/ml) | Inhibiting rate (%) | ||||
Nasopharyngeal carcinoma (CNE2) | Mammary cancer (MCF-7) | Liver cancer (Bel-7402) | Lung cancer (GLC-82) | Large bowel cancer (HT-29) | ||
Compound 8 | 0.8 1.4 2.0 | 31.8 75.4 95.7 | 30.1 56.9 83.4 | 42.2 67.7 91.3 | 26.9 54.2 82.7 | 19.9 43.9 87.2 |
Compound 32 | 0.8 1.4 2.0 | 19.8 71.1 82.2 | 22.9 67.4 94.1 | 31.2 61.0 83.4 | 45.9 71.2 93.0 | 32.4 57.2 86.2 |
Compound 45 | 0.8 1.4 2.0 | 17.5 44.5 91.1 | 22.4 59.1 80.7 | 43.9 66.7 96.4 | 25.3 45.7 89.8 | 31.5 58.7 96.3 |
Compound 67 | 0.8 1.4 2.0 | 22.4 57.3 84.3 | 12.3 46.1 87.9 | 34.4 57.9 97.8 | 31.7 65.8 90.8 | 21.4 57.1 80.8 |
Compound 78 | 0.8 1.4 2.0 | 49.7 87.6 99.7 | 33.6 59.8 96.5 | 30.2 75.2 96.8 | 31.1 66.4 90.1 | 43.4 61.7 92.3 |
Compound 82 | 0.8 1.4 2.0 | 21.8 52.4 78.9 | 18.2 49.4 82.4 | 19.3 52.3 84.6 | 33.6 67.7 96.6 | 40.4 67.8 90.4 |
5 FU 5 fluorouracil | 0.8 1.4 2.0 | 48.8 77.6 98.2 | 39.6 69.8 92.8 | 46.8 72.2 93.6 | 43.9 68.6 95.5 | 36.6 69.8 91.7 |
The result shows that compound 78,82,67,82,45 pairs of nasopharyngeal carcinoma, mammary cancer, liver cancer, lung cancer, large bowel cancers have significant inhibitory effect, and restraining effect is higher than 5 FU 5 fluorouracil.
The above embodiment of the present invention shows: in the series electronic isostere of synthetic irisin, the antitumous effect of a part is higher than the positive control 5 FU 5 fluorouracil, anxious poison experiment to rat shows, compound 74,65,82, when 45 dosage reaches 5g/kg (this dosage is the non-toxic of pharmacopeia regulation), do not find that rat has the poisoning sign, therefore under normal dose, they are safe as medicinal application.
The fusing point of compound 1~86, high resolution mass spectrum, infrared and hydrogen spectrum data
6-methyl-5-formyl radical-4 '-hydroxy-isoflavone (1):
Mp 202-204℃;ESI-MS:280.0743(calc.280.48):IR(KBr)cm
-1:1708(C=O),1715(C=O),3456(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),6.68(d,2H),7.36(d,1H),7.46(d,2H),7.89(d,1H),8.34(s,1H),9.07(s,1H),12.15(s,1H)。
6-methyl-7-formyl radical-4 '-hydroxy-isoflavone (2):
Mp 208-209℃;ESI-MS:280.0740(calc.280.48);IR(KBr)cm
-1:1708(C=O),1715(C=O),3456(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),6.62(d,2H),7.35(d,1H),7.43(d,2H),7.63(d,1H),8.37(s,1H),9.15(s,1H),10.24(s,1H)。
6-methyl-5-cyano group-4 '-hydroxy-isoflavone (3):
Mp 197-198℃;ESI-MS:277.0707(calc.277.0712);IR(KBr)cm
-1:1708(C=O),1745(C≡N),3456(OH);
1H NMR(DMSO-d
6)δppm:2.31(s,3H),6.65(d,2H),7.33(d,1H),7.41(d,2H),7.81(d,1H),8.25(s,1H),9.07(s,1H)。
6-methyl-7-cyano group-4 '-hydroxy-isoflavone (4):
Mp 195-196℃;ESI-MS:277.0715(calc.277.0712);IR(KBr)cm
-1:1710(C=O),1749(C≡N),3447(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),6.67(d,2H),7.05(d,1H),7.41(d,2H),7.62(d,1H),8.26(s,1H),9.11(s,1H)。
6-methyl-5-formyl radical-3 '-nitro-4 '-hydroxy-isoflavone (5):
Mp 225-226℃;ESI-MS:325.0673(calc.325.0676);IR(KBr)cm
-1:1708(C=O),1728(C=O),3456(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),6.94(d,1H),7.36(d,1H),7.85(d×d,1H),7.89(d,1H),8.06(d,1H),8.32(s,1H),11.12(s,1H),12.05(s,1H)。
6-methyl-7-formyl radical-3 '-nitro-4 '-hydroxy-isoflavone (6):
Mp 221-223℃;ESI-MS:325.0675(calc.325.0676);IR(KBr)cm
-1:1712(C=O),1731(C=O),3447(OH);
1H NMR(DMSO-d
6)δppm:2.37(s,3H),6.92(d,1H),7.35(s,1H),7.63(s,1H),7.85(d×d,1H),8.04(d,1H),8.34(s,1H),10.24(s,1H),11.15(s,1H)。
6-methyl-5-cyano group-3 '-nitro-4 '-hydroxy-isoflavone (7):
Mp 219-220℃;ESI-MS:322.0673(calc.322.0676);IR(KBr)cm
-1:1708(C=O),1746(C≡N),3454(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),6.85(d,1H),7.35(d,1H),7.86(d×d,1H),7.90(d,1H),8.11(d,1H),8.27(s,1H),11.09(s,1H)。
6-methyl-7-cyano group-3 '-nitro-4 '-hydroxy-isoflavone (8):
Mp 215-217℃:ESI-MS:325.0669(calc.325.0676);IR(KBr)cm
-1:1708(C=O),1743(C≡N),3451(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),6.95(d,1H),7.05(s,1H),7.67(s,1H),7.81(d×d,1H),8.08(d,1H),8.27(s,1H),10.31(s,1H)。
6-methyl-5-nitro-3 '-nitro-4 '-hydroxy-isoflavone (9):
Mp 219-220℃;ESI-MS:342.0591(calc.342.0587);IR(KBr)cm
-1:1708(C=O),3454(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),6.97(d,1H),7.43(d,1H),7.82(d×d,1H),8.00(d,1H),8.12(d,1H),8.29(s,1H),11.07(s,1H)。
6-methyl-7-nitro-3 '-nitro-4 '-hydroxy-isoflavone (10):
Mp 213-24℃;ESI-MS:342.0582(calc.342.0587);IR(KBr)cm
-1:1713(C=O),3448(OH);
1H NMR(DMSO-d
6)δppm:2.64(s,3H),6.94(d,1H),7.70(s,1H),7.73(d,1H),7.81(d×d,1H),8.08(d,1H),8.27(s,1H),11.10(s,1H)。
6-methyl-5-formyl radical-3 '-formyl radical-4 '-hydroxy-isoflavone (11):
Mp 208-209℃;ESI-MS:308.0765(calc.308.0771);IR(KBr)cm
-1:1708(C=O),3454(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),6.87(d,1H),7.36(d,1H),7.74(d×d,1H),7.68(d,1H),7.89(d,1H),8.31(s,1H),10.23(s,1H),10.25(s,1H),11.73(s,1H)。
6-methyl-7-formyl radical-3 '-formyl radical-4 '-hydroxy-isoflavone (12):
Mp 202-203℃;ESI-MS:308.0761(calc.308.0771);IR(KBr)cm
-1:1708(C=O),3454(OH);
1H NMR(DMSO-d
6)δppm:2.31(s,3H),6.83(d,1H),7.32(s,1H),7.63(d,1H),7.68(d,1H),7.78(d×d,1H),8.36(s,1H),10.25(s,1H),10.28(s,1H),11.69(s,1H)。
6-methyl-5-cyano group-3 '-formyl radical-4 '-hydroxy-isoflavone (13):
Mp 212-214℃;ESI=MS:305.0765(calc.305.0769);IR(KBr)cm
-1:1705(C=O),1746(C≡N),3456(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),6.85(d,1H),7.34(d,1H),7.76(d×d,1H),7.64(d,1H),7.85(d,1H),8.27(s,1H),10.23(s,1H),11.68(s,1H)。
6-methyl-7-cyano group-3 '-formyl radical-4 '-hydroxy-isoflavone (14):
Mp 210-212℃;ESI-MS:305.0761(calc.305.0769);IR(KBr)cm
-1:1711(C=O),1741(C≡N),3451(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),6.87(d,1H),7.02(s,1H),7.62(s,1H),7.66(d,1H),7.74(d×d,1H),8.36(s,1H),10.21(s,1H),11.65(s,1H)。
6-methyl-5-nitro-3 '-formyl radical-4 '-hydroxy-isoflavone (15):
Mp 219-221℃;ESI-MS:325.0638(calc.325.0634);IR(KBr)cm
-1:1713(C=O),3438(OH);
1H NMR(DMSO-d
6)δppm:2.31(s,3H),6.88(d,1H),7.43(d,1H),7.74(d×d,1H),7.68(d,1H),8.00(d,1H),8.33(s,1H),10.16(s,1H),11.57(s,1H)。
6-methyl-7-nitro-3 '-formyl radical-4 '-hydroxy-isoflavone (16):
Mp 216-217℃;ESI-MS:325.0629(calc.325.0634);IR(KBr)cm
-1:1715(C=O),3442(OH);
1H NMR(DMSO-d
6)δppm:2.63(s,3H),6.81(d,1H),7.63(d,1H),7.67(s,1H),7.70(s,1H),7.76(d×d,1H),8.27(s,1H),10.20(s,1H),11.51(s,1H)。
6-methyl-5-nitro-3 '-cyano group-4 '-hydroxy-isoflavone (17):
Mp 217-218℃;ESI-MS:305.0718(calc.305.0714);IR(KBr)cm
-1:1713(C=O),1735(C≡N),3435(OH);
1H NMR(DMSO-d
6)δppm:2.27(s,3H),6.82(d,1H),7.35(d,1H),7.42(d,1H),7.77(d×d,1H),7.90(d,1H),8.30(s,1H),9.73(s,1H),10.21(s,1H)。
6-methyl-7-nitro-3 '-cyano group-4 '-hydroxy-isoflavone (18):
Mp 213-215℃;ESI-MS:305.0709(calc.305.0714);IR(KBr)cm
-1:1723(C=O),1738(C≡N),3446(OH);
1H NMR(DMSO-d
6)δppm:2.38(s,3H),6.87(d,1H),7.35(s,1H),7.39(d,1H),7.63(d,1H),7.72(d×d,1H),8.37(s,1H),9.74(s,1H),10.26(s,1H)。
6-methyl-5-cyano group-3 '-cyano group-4 '-hydroxy-isoflavone (19):
Mp 217-218℃;ESI-MS:302.0758(calc.302.0754);IR(KBr)cm
-1:1708(C=O),1738(C≡N),3442(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),6.85(d,1H),7.32(d,1H),7.38(d,1H),7.72(d×d,1H),7.87(d,1H),8.30(s,1H),9.76(s,1H)。
6-methyl-7-cyano group-3 '-cyano group-4 '-hydroxy-isoflavone (20):
Mp 215-216℃;ESI-MS:302.0749(calc.302.0754);IR(KBr)cm
-1:1708(C=O),1741(C≡N),3458(OH);
1H NMR(DMSO-d
6)δppm:2.38(s,3H),6.84(d,1H),7.05(d,1H),7.37(d,1H),7.62(d,1H),7.72(d×d,1H),8.29(s,1H),9.76(s,1H)。
6-methyl-5-nitro-3 '-cyano group-4 '-hydroxy-isoflavone (21):
Mp 222-224℃;ESI-MS:322.0659(calc.322.0654);IR(KBr)cm
-1:1705(C=O),1732(C≡N),3438(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),6.86(d,1H),7.37(d,1H),7.43(d,1H),7.78(d×d,1H),8.05(d,1H),8.32(s,1H),9.78(s,1H)。
6-methyl-7-nitro-3 '-cyano group-4 '-hydroxy-isoflavone (22):
Mp 217-219℃;ESI-MS:322.0659(calc.322.0654);IR(KBr)cm
-1:1705(C=O),1738(C≡N),3454(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),6.83(d,1H),7.37(d,1H),7.69(s,1H),7.72(s,1H),7.75(d×d,1H),8.35(s,1H),9.72(s,1H)。
6-methyl-5-methylol-4 '-hydroxy-isoflavone (23):
Mp 228-229℃;ESI-MS:282.0921(calc.282.0917):IR(KBr)cm
-1:1705(C=O),3443(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),4.79(s,2H),5.39(s,1H),6.68(d,2H),7.16(d,1H),7.46(d,2H),7.54(d,1H),8.35(s,1H),9.26(s,1H)。
6-methyl-7-methylol-4 '-hydroxy-isoflavone (24):
Mp 224-225℃;ESI-MS:282.0925(calc.282.0917);IR(KBr)cm
-1:1709(C=O),3447(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),4.72(s,2H),5.32(s,1H),6.63(d,2H),6.73(s,1H),7.37(s,2H),7.49(d,1H),8.32(s,1H),9.54(s,1H)。
6-methyl-5-amino-4 '-hydroxy-isoflavone (25):
Mp 230-231℃;ESI-MS:267.0950(calc.267.0945);IR(KBr)cm
-1:1714(C=O),3446(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),5.85(s,2H),6.63(d,2H),6.91(d,1H),6.97(d,2H),7.48(d,1H),8.31(s,1H),9.31(s,1H)。
6-methyl-7-amino-4 '-hydroxy-isoflavone (26):
Mp 228-229℃;ESI-MS:267.0947(calc.267.0945);IR(KBr)cm
-1:1709(C=O),3441(OH);
1H NMR(DMSO-d
6)δppm:2.31(s,3H),5.82(s,2H),6.00(s,1H),7.19(s,1H),6.64(d,2H),7.48(d,2H),8.31(s,1H),9.30(s,1H)。
6-methyl-5-chloro-4 '-hydroxy-isoflavone (27):
Mp 234-235℃;ESI-MS:286.0427(calc.286.0421);IR(KBr)cm
-1:1707(C=O),3440(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),6.68(d,2H),7.11(d,1H),7.46(d,2H),7.51(d,1H),8.37(s,1H),9.29(s,1H)。
6-methyl-7-chloro-4 '-hydroxy-isoflavone (28):
Mp 231-233℃;ESI-MS:286.0415(calc.286.0421);IR(KBr)cm
-1:1708(C=O),3447(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),6.61(d,2H),6.81(s,1H),7.35(s,1H),7.49(d,2H),8.31(s,1H),9.32(s,1H)。
6-methyl-5-bromo-4 '-hydroxy-isoflavone (29):
Mp 238-242℃;ESI-MS:329.9938(calc.329.9932);IR(KBr)cm
-1:1713(C=O),3438(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),6.65(d,2H),7.05(d,1H),7.46(d,2H),7.55(d,1H),8.34(s,1H),9.48(s,1H)。
6-methyl-7-bromo-4 '-hydroxy-isoflavone (30):
Mp 235-237℃;ESI-MS:329.9927(calc.329.9932);IR(KBr)cm
-1:1713(C=O),3441(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),6.62(d,2H),6.97(d,1H),7.33(s,1H),7.48(d,2H),8.36(s,1H),9.43(s,1H)。
6-methyl-5-fluoro-4 '-hydroxy-isoflavone (31):
Mp 217-218℃;ESI-MS:270.0754(calc.270.0763);IR(KBr)cm
-1:1715(C=O),3436(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),6.67(d,2H),7.15(d,1H),7.38(d,1H),7.49(d,2H),8.31(s,1H),9.47(s,1H)。
6-methyl-7-bromo-4 '-hydroxy-isoflavone (32):
Mp 213-215℃;ESI-MS:270.0758(calc.270.0763);IR(KBr)cm
-1:1712(C=O),3438(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),6.51(s,1H),6.64(d,2H),7.42(s,1H),7.49(d,2H),8.33(s,1H),9.45(s,1H)。
6-methyl-5-formyl radical-3 '-amino-4 '-hydroxy-isoflavone (33):
Mp 231-233℃;ESI-MS:295.0845(calc.295.0841);IR(KBr)cm
-1:1707(C=O),3434(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),5.82(s,2H),6.33(d,1H),6.43(d,1H),6.82(d×d,1H),7.36(d,1H),7.89(d,1H),8.12(s,1H),9.47(s,1H),10.24(s,1H)。
6-methyl-7-formyl radical-3 '-amino-4 '-hydroxy-isoflavone (34):
Mp 227-228℃;ESI-MS:295.0837(calc.295.0841);IR(KBr)cm
-1:1707(C=O),3443(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),5.81(s,2H),6.31(d,1H),6.45(d,1H),6.85(d×d,1H),7.32(s,1H),7.63(s,1H),8.15(s,1H),9.41(s,1H),10.28(s,1H)。
6-methyl-5-methylol-3 '-nitro-4 '-hydroxy-isoflavone (35):
Mp 233-235℃;ESI-MS:327.0754(calc.327.0761);IR(KBr)cm
-1:1713(C=O),3438(OH);
1H NMR(DMSO-d
6)δppm:2.31(s,3H),4.79(s,2H),5.39(s,1H),6.94(d,1H),7.10(d,1H),7.54(d,1H),7.85(d×d,1H),8.06(d,1H),8.37(s,1H),11.84(s,1H)。
6-methyl-7-methylol-3 '-nitro-4 '-hydroxy-isoflavone (36):
Mp 230-232℃;ESI-MS:327.0751(calc.327.0761);IR(KBr)cm
-1:1713(C=O),3441(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),4.72(s,2H),5.17(s,1H),6.73(s,1H),6.94(d,1H),7.37(s,1H),7.81(d×d,1H),8.10(d,1H),8.33(s,1H),11.80(s,1H)。
6-methyl-5-methylol-3 '-amino-4 '-hydroxy-isoflavone (37):
Mp 237-238℃;ESI-MS:297.1034(calc.297.1028);IR(KBr)cm
-1:1706(C=O),3433(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),4.71(s,2H),5.32(s,1H),5.82(s,2H),6.33(d,1H),6.43(d,1H),6.82(d×d,1H),7.10(d,1H),7.54(d,1H),8.34(s,1H),8.67(s,1H)。
6-methyl-7-methylol-3 '-amino-4 '-hydroxy-isoflavone (38):
Mp 233-234℃;ESI-MS:297.1021(calc.297.1028);IR(KBr)cm
-1:1714(C=O),3429(OH);
1H NMR(DMSO-d
6)δppm:2.29(s,3H),4.75(s,2H),5.27(s,1H),5.83(s,2H),6.35(d,1H),6.41(d,1H),6.73(s,1H),6.85(d×d,1H),7.37(s,1H),8.31(s,1H),8.69(s,1H)。
6-methyl-5-formyl radical-3 '-fluoro-4 '-hydroxy-isoflavone (39):
Mp 215-216℃;ESI-MS:298.0627(calc.298.0632);IR(KBr)cm
-1:1715(C=O),3437(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),6.66(d,2H),6.84(d,1H),7.23(d×d,1H),7.23(d,1H),7.89(d,1H),8.36(s,1H),9.54(s,1H)。
6-methyl-7-formyl radical-3 '-fluoro-4 '-hydroxy-isoflavone (40):
Mp 213-215℃;ESI-MS:298.0637(calc.298.0632);1R(KBr)cm
-1:1711(C=O),3440(OH);
1H NMR(DMSO-d
6)δppm:2.37(s,3H),6.65(d,2H),6.86(d,1H),7.25(d×d,1H),7.35(s,1H),7.63(s,1H),8.33(s,1H),9.51(s,1H)。
6-methyl-5-methylol-3 '-chloro-4 '-hydroxy-isoflavone (41):
Mp 235-236℃;ESI-MS:316.0534(calc.316.0529);IR(KBr)cm
-1:1717(C=O),3432(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),4.79(s,2H),5.39(s,1H),6.62(d,1H),7.09(d,1H),7.14(d,1H),7.32(d×d,1H),7.54(d,1H),8.31(s,1H),9.47(s,1H)。
6-methyl-7-methylol-3 '-chloro-4 '-hydroxy-isoflavone (42):
Mp 230-232℃;ESI-MS:316.0526(calc.316.0529);IR(KBr)cm
-1:1713(C=O),3440(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),4.75(s,2H),5.41(s,1H),6.64(d,1H),6.73(s,1H),7.15(d,1H),7.31(d×d,1H),7.38(d,1H),8.37(s,1H),9.45(s,1H)。
6-methyl-5-methylol-3 '-bromo-4 '-hydroxy-isoflavone (43):
Mp 240-241℃;ESI-MS:360.1351(calc.360.1357);IR(KBr)cm
-1:1711(C=O),3438(OH);
1H NMR(DMSO-d
6)δppm:2.36(s,3H),4.73(s,2H),5.36(s,1H),6.57(d,1H),7.10(d,1H),7.30(d,1H),7.40(d×d,1H),7.57(d,1H),8.33(s,1H),9.50(s,1H)。
6-methyl-7-methylol-3 '-bromo-4 '-hydroxy-isoflavone (44):
Mp 237-238℃;ESI-MS:360.1362(calc.360.1357);IR(KBr)cm
-1:1713(C=O),3437(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),4.75(s,2H),5.27(s,1H),6.53(d,1H),6.71(s,1H),7.29(d,1H),7.36(s,1H),7.42(d×d,1H),8.34(s,1H),9.49(s,1H)。
6-methyl-5-formyl radical-3 '-methylol-4 '-hydroxy-isoflavone (45):
Mp 226-227℃;ESI-MS:310.0818(calc.310.0813);IR(KBr)cm
-1:1712(C=O),3438(OH);
1H NMR(DMSO-d
6)δppm:2.31(s,3H),4.76(s,2H),5.38(s,1H),6.61(d,1H),7.06(d,1H),7.36(d,1H),7.42(d×d,1H),7.89(d,1H),8.35(s,1H),9.47(s,1H)。
6-methyl-7-formyl radical-3 '-methylol-4 '-hydroxy-isoflavone (46):
Mp 223-225℃;ESI-MS:310.0821(calc.310.0813);IR(KBr)cm
-1:1709(C=O),3432(OH);
1H NMR(DMSO-d
6)δppm:2.30(s,3H),4.75(s,2H),5.34(s,1H),6.63(d,1H),7.08(d,1H),7.34(s,1H),7.39(d×d,1H),7.63(s,1H),8.31(s,1H),9.43(s,1H)。
6-methyl-5-methylol-3 '-formyl radical-4 '-hydroxy-isoflavone (47):
Mp 224-225℃;ESI-MS:310.0815(calc.310.0813);IR(KBr)cm
-1:1716(C=O),3433(OH);
1H NMR(DMSO-d
6)δppm:2.37(s,3H),4.78(s,2H),5.40(s,1H),6.86(d,1H),7.10(d,1H),7.54(d,1H),7.68(d,1H),7.74(d×d,1H),8.32(s,1H),10.13(s,1H),11.54(s,1H)。
6-methyl-7-methylol-3 '-formyl radical-4 '-hydroxy-isoflavone (48):
Mp 221-223℃;ESI-MS:310.0819(calc.310.0813);IR(KBr)cm
-1:1709(C=O),3437(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),4.71(s,2H),5.36(s,1H),6.73(s,1H),6.87(d,1H),7.36(s,1H),7.66(d,1H),7.71(d×d,1H),8.33(s,1H),10.11(s,1H),11.57(s,1H)。
6-methyl-5-methylol-3 '-methylol-4 '-hydroxy-isoflavone (49):
Mp 227-228℃;ESI-MS:312.1049(calc.312.1056);IR(KBr)cm
-1:1716(C=O),3440(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),4.75(s,2H),4.79(s,2H),5.38(s,1H),5.40(s,1H),6.60(d,1H),7.03(d,1H),7.11(d,1H),7.33(d×d,1H),7.54(d,1H),8.34(s,1H),9.61(s,1H)。
6-methyl-7-methylol-3 '-methylol-4 '-hydroxy-isoflavone (50):
Mp 223-225℃;ESI-MS:312.1061(calc.312.1056);IR(KBr)cm
-1:1710(C=O),3439(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),4.71(s,2H),4.77(s,2H),5.36(s,1H),5.41(s,1H),6.66(d,1H),6.72(s,1H),7.08(d,1H),7.36(s,1H),7.40(d×d,1H),8.31(s,1H),9.71(s,1H)。
6-methyl-5-fluoro-3 '-methylol-4 '-hydroxy-isoflavone (51):
Mp 213-214℃;ESI-MS:300.0874(calc.300.0878);IR(KBr)cm
-1:1718(C=O),3437(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),4.75(s,2H),5.38(s,1H),6.62(d,1H),7.06(d,1H),7.15(d,1H),7.38(d,1H),7.40(d×d,1H),8.30(s,1H),9.58(s,1H)。
6-methyl-7-fluoro-3 '-methylol-4 '-hydroxy-isoflavone (52):
Mp 211-212℃;ESI-MS:300.0871(calc.300.0878);IR(KBr)cm
-1:1714(C=O),3435(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),4.76(s,2H),5.34(s,1H),6.60(d,1H),6.51(s,1H),7.10(d,1H),7.38(d×d,1H),7.43(s,1H),8.31(s,1H),9.55(s,1H)。
6-methyl-5-chloro-3 '-formyl radical-4 '-hydroxy-isoflavone (53):
Mp 216-217℃;ESI-MS:314.0367(calc.314.0371);IR(KBr)cm
-1:1718(C=O),3437(OH);
1H NMR(DMSO-d
6)δppm:2.37(s,3H),6.68(d,1H),6.87(d,1H),7.11(d,1H),7.49(d,1H),7.75(d×d,1H),8.31(s,1H),10.12(s,1H),11.34(s,1H)。
6-methyl-7-chloro-3 '-formyl radical-4 '-hydroxy-isoflavone (54):
Mp 213-214℃;ESI-MS:314.0361(calc.314.0371);IR(KBr)cm
-1:1714(C=O),3435(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),6.80(s,1H),6.85(d,1H),7.38(s,1H),7.68(d,1H),7.75(d×d,1H),8.32(s,1H),10.13(s,1H),11.35(s,1H)。
6-methyl-5-bromo-3 '-methylol-4 '-hydroxy-isoflavone (55):
Mp 235-236℃;ESI-MS:360.0071(calc.360.0075);IR(KBr)cm
-1:1714(C=O),3430(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),4.76(s,2H),5.37(s,1H),6.62(d,1H),7.01(d,1H),7.09(d,1H),7.34(d×d,1H),7.59(d,1H),8.32(s,1H),9.61(s,1H)。
6-methyl-7-bromo-3 '-methylol-4 '-hydroxy-isoflavone (56):
Mp 231-232℃;ESI-MS:360.0062(calc.360.0075);IR(KBr)cm
-1:1707(C=O),3433(OH);
1H NMR(DMSO-d
6)δppm:2.31(s,3H),4.77(s,2H),5.35(s,1H),6.65(d,1H),6.97(s,1H),7.09(d,1H),7.32(d,1H),7.40(d×d,1H),8.34(s,1H),9.58(s,1H)。
6-methyl-5-methylol-3 '-cyano group-4 '-hydroxy-isoflavone (57):
Mp 228-229℃;ESI-MS:307.0864(calc.307.0871);IR(KBr)cm
-1:1712(C=O),3448(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),4.77(s,2H),5.32(s,1H),6.82(d,1H),7.10(d,1H),7.38(d,1H),7.53(d,1H),7.71(d×d,1H),8.35(s,1H),9.71(s,1H)。
6-methyl-7-methylol-3 '-cyano group-4 '-hydroxy-isoflavone (58):
Mp 223-225℃;ESI-MS:307.0860(calc.307.0871);IR(KBr)cm
-1:1709(C=O),3441(OH);
1H NMR(DMSO-d
6)6ppm:2.32(s,3H),4.71(s,2H),5.30(s,1H),6.71(s,1H),6.75(d,1H),7.34(s,1H),7.41(d,1H),7.73(d×d,1H),8.31(s,1H),9.79(s,1H)。
6-methyl-5-fluoro-3 '-cyano group-4 '-hydroxy-isoflavone (59):
Mp 212-214℃;ESI-MS:295.0618(calc.295.0613);IR(KBr)cm
-1:1717(C=O),1743(C≡N),3443(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),6.75(d,1H),7.13(d,1H),7.38(d,1H),7.42(d,1H),7.73(d×d,1H),8.38(s,1H),9.69(s,1H)。
6-methyl-7-fluoro-3 '-cyano group-4 '-hydroxy-isoflavone (60):
Mp 209-211℃;ESI-MS:295.0607(calc.295.0613);IR(KBr)cm
-1:1713(C=O),1738(C≡N),3450(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),6.54(d,1H),6.81(s,1H),7.38(d,1H),7.45(s,1H),7.75(d×d,1H),8.31(s,1H),9.58(s,1H)。
6-methyl-5-chloro-3 '-cyano group-4 '-hydroxy-isoflavone (61):
Mp 217-219℃;ESI-MS:311.0312(calc.311.0317);IR(KBr)cm
-1:1716(C=O),1731(C≡N),3436(OH);
1H NMR(DMSO-d
6)δppm:2.35(s,3H),6.82(d,1H),7.12(d,1H),7.34(d,1H),7.51(d,1H),7.76(d×d,1H),8.35(s,1H),9.66(s,1H)。
6-methyl-7-chloro-3 '-cyano group-4 '-hydroxy-isoflavone (62):
Mp 212-214℃;ESI-MS:311.0312(calc.311.0317);IR(KBr)cm
-1:1712(C=O),1736(C≡N),3447(OH);
1H NMR(DMSO-d
6)δppm:2.32(s,3H),6.77(d,1H),6.84(s,1H),7.36(s,1H),7.39(d,1H),7.72(d×d,1H),8.33(s,1H),9.61(s,1H)。
6-methyl-5-bromo-3 '-cyano group-4 '-hydroxy-isoflavone (63):
Mp 231-233℃;ESI-MS:354.9812(calc.354.9819);IR(KBr)cm
-1:1718(C=O),1732(C≡N),3441(OH);
1H NMR(DMSO-d
6)δppm:2.33(s,3H),6.82(d,1H),7.02(d,1H),7.37(d,1H),7.51(d,1H),7.72(d×d,1H),8.32(s,1H),9.61(s,1H)。
6-methyl-7-bromo-3 '-cyano group-4 '-hydroxy-isoflavone (64):
Mp 227-228℃;ESI-MS:354.9822(calc.354.9819);IR(KBr)cm
-1:1714(C=O),1740(C≡N),3452(OH);
1H NMR(DMSO-d
6)δppm:2.34(s,3H),6.81(d,1H),6.97(s,1H),7.31(s,1H),7.37(d,1H),7.75(d×d,1H),8.31(s,1H),9.67(s,1H)。
5,7-two bromo-6-hydroxyls-3-p-methoxyphenyl-4-quinolinone (65):
Mp 256-258℃;ESI-MS:481.9130(calc.481.9122);IR(KBr)cm
-1:1608(C=C),1698(C=O),3460(NH,OH);
1H NMR(DMSO-d
6)δppm:3.45(s,3H),4.02(s,3H),6.65(s,1H),7.30(d,1H),7.69(d,1H),7.91(d,1H),8.12(s,1H),13.29(d,1H)。
5,7-two bromo-6-methoxyl groups-3-p-methoxyphenyl-4-quinolinone (66):
Mp 251-253℃;ESI-MS:436.9351(calc.436.9347);IR(KBr)cm
-1:1612(C=C),1698(C=O),3452(NH);
1H NMR(DMSO-d
6)δppm:3.73(s,3H),3.85(s,3H),6.67(s,1H),6.72(d,2H),7.52(d,2H),8.35(d,1H),12.23(d,1H)。
5,7-two bromo-6-hydroxyls-3-p-nitrophenyl-4-quinolinone (67):
Mp 253-254℃;ESI-MS:437.8975(calc.437.8969);IR(KBr)cm
-1:1621(C=C),1698(C=O),3455(NH,OH);
1H NMR(DMSO-d
6)δppm:6.70(s,1H),7.43(d,2H),8.14(d,2H),8.30(d,1H),9.12(s,1H),12.23(d,1H)。
5,7-two bromo-6-methoxyl groups-3-p-nitrophenyl-4-quinolinone (68):
Mp 248-249℃;ESI-MS:451.9031(calc.451.9039);IR(KBr)cm
-1:1621(C=C),1698(C=O),3455(NH);
1H NMR(DMSO-d
6)δppm:3.48(s,3H),6.29(s,1H),7.43(d,2H),8.14(d,2H),8.30(d,1H),12.23(d,1H)。
5,7-two bromo-6-hydroxyls-3-p-amino phenyl-4-quinolinone (69):
ESI-MS:407.9168(calc.407.9161);IR(KBr)cm
-1:1621(C=C),1698(C=O),3455(NH,OH);
1H NMR(DMSO-d
6)δppm:6.29(s,1H),7.43(d,2H),8.14(d,2H),8.30(d,1H),9.21(s,1H),12.23(d,1H)。
5,7-two bromo-6-methoxyl groups-3-p-amino phenyl-4-quinolinone (70):
Mp 253-254℃;ESI-MS:421.9355(calc.421.9359);IR(KBr)cm
-1:1617(C=C),1698(C=O),3463(NH);
1H NMR(DMSO-d
6)δppm:3.46(s,3H),5.85(s,2H),6.41(d,2H),6.55(s,1H),7.05(d,2H),8.15(d,1H),12.80(d,1H)。
5,7-two bromo-6-hydroxyl-3-are to fluorophenyl-4-quinolinone (71):
Mp 236-238℃;ESI-MS:410.8911(calc.410.8917);IR(KBr)cm
-1:1621(C=C),1698(C=O),3455(NH,OH);
1H NMR(DMSO-d
6)δppm:6.55(s,1H),7.43(d,2H),8.14(d,2H),8.15(d,1H),8.75(s,1H),12.80(d,1H)。
5,7-two bromo-6-methoxyl group-3-are to fluorophenyl-4-quinolinone (72):
Mp 233-234℃;ESI-MS:424.9161(calc.424.9155);IR(KBr)cm
-1:1617(C=C),1685(C=O),3477(NH);
1H NMR(DMSO-d
6)δppm:3.73(s,3H),6.55(s,1H),7.43(d,2H),8.14(d,2H),8.15(d,1H),12.80(d,1H)。
5,7-two bromo-6-hydroxyls-3-rubigan-4-quinolinone (73):
Mp 238-240℃;ESI-MS:426.8611(calc.426.8617);IR(KBr)cm
-1:1621(C=C),1698(C=O),3455(NH,OH);
1H NMR(DMSO-d
6)δppm:6.55(s,1H),7.22(d,2H),7.24(d,2H),8.15(d,1H),8.75(s,1H),12.80(d,1H)。
5,7-two bromo-6-methoxyl groups-3-rubigan-4-quinolinone (74):
Mp 234-235℃;ESI-MS:440.8834(calc.440.8829);IR(KBr)cm
-1:1620(C=C),1685(C=O),3470(NH);
1H NMR(DMSO-d
6)δppm:3.65(s,3H),6.55(s,1H),7.25(d,2H),7.60(d,2H),8.15(d,1H),12.80(d,1H)。
5,7-two bromo-6-hydroxyl-3-are to bromophenyl-4-quinolinone (75):
Mp 239-241℃;ESI-MS:470.8164(calc.470.8170);IR(KBr)cm
-1:1618(C=C),1701(C=O),3455(NH,OH);
1H NMR(DMSO-d
6)δppm:6.70(s,1H),7.19(d,2H),7.38(d,2H),8.20(d,1H),9.04(s,1H),12.87(d,1H)。
5,7-two bromo-6-methoxyl group-3-are to bromophenyl-4-quinolinone (76):
Mp 237-239℃;ESI-MS:484.8366(calc.484.8359);IR(KBr)cm
-1:1620(C=C),1677(C=O),3470(NH);
1H NMR(DMSO-d
6)δppm:3.81(s,3H),6.70(s,1H),7.19(d,2H),7.38(d,2H),8.20(d,1H),12.87(d,1H)。
6-hydroxyl-3-(4-hydroxyl-3-nitrophenyl)-4-quinolinone (77):
Mp 232-235℃;ESI-MS:298.0611(calc.298.0620);IR(KBr)cm
-1:1618(C=C),1701(C=O),3458(NH,OH);
1H NMR(DMSO-d
6)δppm:6.76(d,1H),6.94(d,1H),7.03(s,1H),7.73(d,1H),7.85(d,1H),8.06(s,1H),8.31(d,1H),9.01(s,1H),10.58(s,1H),12.07(d,1H)。
6-methoxyl group-3-(4-hydroxyl-3-nitrophenyl)-4-quinolinone (78):
Mp 230-231℃;ESI-MS:312.0705(calc.312.0710);IR(KBr)cm
-1:1618(C=C),1705(C=O),3463(NH,OH);
1H NMR(DMSO-d
6)δppm:4.05(s,1H),6.94(d,1H),7.52(d,1H),7.66(s,1H),7.79(d,1H),7.85(d,1H),8.06(s,1H),8.31(d,1H),10.58(s,1H),12.07(d,1H)。
6-hydroxyl-3-(4-hydroxyl-3-aminophenyl)-4-quinolinone (79):
Mp 247-249℃;ESI-MS:268.0845(calc.268.0840);IR(KBr)cm
-1:1620(C=C),1711(C=O),3447(NH,OH);
1H NMR(DMSO-d
6)δppm:5.85(s,2H),6.33(s,1H),6.43(d,1H),6.67(d,1H),6.82(d,1H),7.03(s,1H),7.73(d,1H),8.35(d,1H),8.91(s,1H),10.23(s,1H),12.33(d,1H)。
6-methoxyl group-3-(4-hydroxyl-3-aminophenyl)-4-quinolinone (80):
Mp 241-242℃;ESI-MS:282.1007(calc.282.1011);IR(KBr)cm
-1:1620(C=C),1711(C=O),3447(NH,OH);
1H NMR(DMSO-d
6)δppm:3.91(s,1H),6.33(s,1H),6.43(d,1H),6.62(d,1H),6.82(d,1H),7.52(d,1H),7.66(s,1H),7.79(d,1H),8.35(d,1H),10.14(s,1H),12.09(d,1H)。
6-hydroxyl-3-(4-hydroxyl-3-fluorophenyl)-4-quinolinone (81):
Mp 235-236℃;ESI-MS:271.0630(calc.271.0624);IR(KBr)cm
-1:1615(C=C),1697(C=O),3467(NH,OH);
1H NMR(DMSO-d
6)δppm:6.66(d,1H),6.76(d,1H),6.84(d,1H),7.03(s,1H),7.23(d,1H),7.73(d,1H),8.19(d,1H),8.91(s,1H),9.93(s,1H),12.23(d,1H)。
6-methoxyl group-3-(4-hydroxyl-3-fluorophenyl)-4-quinolinone (82):
Mp 233-234℃;ESI-MS:285.0877(calc.285.0870);IR(KBr)cm
-1:1605(C=C),1697(C=O),3461(NH,OH);
1H NMR(DMSO-d
6)δppm:3.88(s,1H),6.66(d,1H),6.84(s,1H),7.23(d,1H),7.52(d,1H),7.62(s,1H),7.75(d,1H),8.35(d,1H),9.91(s,1H),12.12(d,1H)。
6-hydroxyl-3-(4-hydroxyl-3-chloro-phenyl-)-4-quinolinone (83):
Mp 237-239℃;ESI-MS:287.0366(calc.287.0370);IR(KBr)cm
-1:1615(C=C),1697(C=O),3467(NH,OH);
1H NMR(DMSO-d
6)δppm:6.62(d,1H),6.76(d,1H),7.03(s,1H),7.14(s,1H),7.34(d,1H),7.73(d,1H),8.19(d,1H),8.89(s,1H),8.91(s,1H),12.23(d,1H)。
6-methoxyl group-3-(4-hydroxyl-3-chloro-phenyl-)-4-quinolinone (84):
Mp 233-234℃;ESI-MS:301.0521(calc.301.2529);IR(KBr)cm
-1:1605(C=C),1708(C=O),3461(NH,OH);
1H NMR(DMSO-d
6)δppm:3.85(s,1H),6.60(d,1H),7.14(s,1H),7.34(d,1H),7.55(d,1H),7.66(s,1H),7.78(d,1H),8.32(d,1H),9.77(s,1H),12.12(d,1H)。
6-hydroxyl-3-(4-hydroxyl-3-bromophenyl)-4-quinolinone (85):
Mp 241-242℃;ESI-MS:330.9824(calc.330.9816);IR(KBr)cm
-1:1609(C=C),1689(C=O),3461(NH,OH);
1H NMR(DMSO-d
6)δppm:6.57(d,1H),6.74(d,1H),7.08(s,1H),7.30(s,1H),7.40(d×d,1H),7.78(d,1H),8.14(d,1H),8.89(s,1H),8.95(s,1H),12.27(d,1H)。
6-methoxyl group-3-(4-hydroxyl-3-bromophenyl)-4-quinolinone (86):
Mp 233-234℃;ESI-MS:345.0019(calc.345.0016);IR(KBr)cm
-1:1612(C=C),1701(C=O),3464(NH,OH);
1H NMR(DMSO-d
6)δppm:3.91(s,1H),6.57(d,1H),7.30(d,1H),7.42(d×d,1H),7.52(d,1H),7.68(s,1H),7.78(d,1H),8.32(d,1H),9.81(s,1H),12.19(d.1H)。
Claims (4)
1. the isostere of a class tectorigenin is characterized in that they have following general structure:
Among the formula II, when X during for O for replacing isoflavones, wherein:
R
1=H, R
2=R, R
3=CHO and R
4=OR, then R
5=R, NO
2, CHO, CN, NR
2, F or CH
2OH;
R
1=H, R
2=R, R
3=CN and R
4=OR, then R
5=R, NO
2, CHO or CN;
R
1=H, R
2=R, R
3=NO
2And R
4=OR, then R
5=NO
2, CHO or CN
R
1=H, R
2=R, R
3=CH
2OH and R
4=OR, then R
5=R, NO
2, NR
2, Cl, Br, CHO, CH
2OH or CN;
R
1=H, R
2=R, R
3=NR
2And R
4=OR, then R
5=R;
R
1=H, R
2=R, R
3=Cl and R
4=OR, then R
5=R, CHO or CN;
R
1=H, R
2=R, R
3=Br and R
4=OR, then R
5=R, CH
2OH or CN;
R
1=H, R
2=R, R
3=F and R
4=OH, then R
5=R, CH
2OH or CN;
R
1=CHO, R
2=R, R
3=R and R
4=OR, then R
5=R, NO
2, CHO, CN, NR
2, F or CH
2OH;
R
1=CN, R
2=R, R
3=R and R
4=OR, then R
5=R, NO
2, CHO or CN;
R
1=NO
2, R
2=R, R
3=R and R
4=OR, then R
5=NO
2, CHO or CN;
R
1=CH
2OH, R
2=R, R
3=R and R
4=OR, then R
5=H, NO
2, NR
2, CHO, Cl, Br, CH
2OH or CN;
R
1=NR
2, R
2=R, R
3=R and R
4=OR, then R
5=R;
R
1=Cl, R
2=R, R
3=R and R
4=OR, then R
5=R, CHO or CN;
R
1=Br, R
2=R, R
3=R and R
4=OR, then R
5=R, CH
2OH or CN;
R
1=F, R
2=R, R
3=R and R
4=OR, then R
5=R, CH
2OH or CN;
Described R=H, CH
3Or C
2H
5,
Among the formula II, when X is a substituted 4-quinolinone during for NH, wherein:
R
1And R
3=Br, R
2=OR and R
5=R, then R
4=NO
2, NR
2, F, Cl, Br or OCH
3
R
1And R
3=H, R
2=OR or OCH
3And R
4=OR, then R
5=NO
2, NR
2, F, Cl or Br; Described R=H, CH
3Or C
2H
5
2. one kind prepares the method that the described Roofirisrhizome flavin non polar isostere of claim 1 replaces isoflavones, it is characterized in that it is made up of the following step basically:
Step 1. is with 4-methyl-3-R
3-5-R
1-phenol and 4-hydroxyl-3-R
5-benzyl cyanide is dissolved in anhydrous Et
2Among the O, the ratio of their amount of substance is: 4-methyl-3-R
3-5-R
1-phenol: 4-hydroxyl-3-R
5-benzyl cyanide=1: 1 feeds exsiccant HCl gas at ice bath and under stirring then, and reaction 24h obtains 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone and 3-methyl-2-R
1-4-R
3-6,4 '-dihydroxyl phenylbenzyl ketone,
Step 2. is with 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone and 3-methyl-2-R
1-4-R
3-6,4 '-dihydroxyl phenylbenzyl ketone carries out column chromatography by silicagel column, isolates 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone,
Step 3. is with 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone is dissolved in the dry DMF, slowly drips BF
3Et
2O is warming up to 40~60 ℃, splashes into CH
3SO
2The DMF solution of Cl, the ratio of the amount of substance of three materials is: 3-methyl-2-R
3-4-R
1-6,4 '-dihydroxyl phenylbenzyl ketone: BF
3Et
2O: CH
3SO
2Cl=1: 3: 2~1: 10: 6, be warming up to 60~90 ℃, reaction 1h generates Roofirisrhizome flavin non polar isostere and replaces isoflavones.
3. method for preparing the described Roofirisrhizome flavin non polar isostere substituted 4-quinolinone of claim 1 is characterized in that it is made up of the following step basically:
Step 1. is with 3-R
3-4-R
2-5-R
1-aniline is dissolved in the dehydrated alcohol, adds 2-(4 '-R
4-3 '-R
5-phenyl)-and the formyl radical ethyl acetate, 3-R
3-4-R
2-5-R
1-aniline and 2-(4 '-R
4-3 '-R
5-phenyl)-ratio of the amount of substance of formyl radical ethyl acetate is: 3-R
3-4-R
2-5-R
1-aniline: 2-(4 '-R
4-3 '-R
5-phenyl)-and the formyl radical ethyl acetate=1: 1~1: 2, at room temperature stir 5~24h, get compound IV:
Step 2. is being heated to the compound IV that step 1 obtains between 80~150 ℃ in the presence of the polyphosphoric acid, obtain the Roofirisrhizome flavin non polar isostere substituted 4-quinolinone.
4. the application of the described Roofirisrhizome flavin non polar isostere of claim 1 in the preparation antitumor drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610040665.0A CN1850817A (en) | 2006-05-26 | 2006-05-26 | Roofirisrhizome flavin non polar isostere, and its preparing method and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610040665.0A CN1850817A (en) | 2006-05-26 | 2006-05-26 | Roofirisrhizome flavin non polar isostere, and its preparing method and use |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1850817A true CN1850817A (en) | 2006-10-25 |
Family
ID=37132319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610040665.0A Pending CN1850817A (en) | 2006-05-26 | 2006-05-26 | Roofirisrhizome flavin non polar isostere, and its preparing method and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1850817A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101797247A (en) * | 2010-04-09 | 2010-08-11 | 中国人民解放军第二军医大学 | Application of isoflavone compound in preparation of anti-tumor drug or food |
CN101139335B (en) * | 2007-10-17 | 2010-12-01 | 北京珅奥基医药科技有限公司 | Use of 7-hydroxy-3-[(4-hydroxy)-3-((E)-3,7-dimethyl-octyl-2,6-diolefin)phenyl]-4H-1-benzopyran-4-ketone |
CN102309479A (en) * | 2011-06-17 | 2012-01-11 | 中国人民解放军第二军医大学 | Application of isoflavone compound in preparation of medicaments or foods for resisting tumors |
CN102718656A (en) * | 2012-06-15 | 2012-10-10 | 济南诚汇双达化工有限公司 | Preparation method of 2-(4-hydroxyphenyl)-propanedioic acidl-[(4-methoxyphenyl)methyl]ester |
CN107118195A (en) * | 2017-06-02 | 2017-09-01 | 云南中烟工业有限责任公司 | A kind of isoflavonoid that can extend the pure tobacco oil shelf-life and preparation method and application |
CN107417612A (en) * | 2017-07-25 | 2017-12-01 | 广州大学 | A kind of synthetic method of quinoline |
CN107417611A (en) * | 2017-07-25 | 2017-12-01 | 广州大学 | One kind 3(4 methoxyphenyls)The synthetic method of the bromoquinoline of 6 methoxyl group, 4 chlorine 5,7 2 |
CN107501174A (en) * | 2017-07-25 | 2017-12-22 | 广州大学 | A kind of synthetic method of quinoline |
CN107501175A (en) * | 2017-07-25 | 2017-12-22 | 广州大学 | A kind of synthetic method of quinoline |
CN107522656A (en) * | 2017-07-25 | 2017-12-29 | 南京大学 | One kind 3(4 methoxyphenyls)The synthetic method of the bromoquinoline of 6 methoxyl group, 4 chlorine 5,7 2 |
CN108685921A (en) * | 2017-12-19 | 2018-10-23 | 广州大学 | A kind of application of the quinoline of N isosteres iridin in medicines resistant to liver cancer |
CN108863818A (en) * | 2018-06-28 | 2018-11-23 | 江苏新瑞药业有限公司 | A kind of synthetic method of pair of amino metacresol |
-
2006
- 2006-05-26 CN CN200610040665.0A patent/CN1850817A/en active Pending
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101139335B (en) * | 2007-10-17 | 2010-12-01 | 北京珅奥基医药科技有限公司 | Use of 7-hydroxy-3-[(4-hydroxy)-3-((E)-3,7-dimethyl-octyl-2,6-diolefin)phenyl]-4H-1-benzopyran-4-ketone |
CN101797247A (en) * | 2010-04-09 | 2010-08-11 | 中国人民解放军第二军医大学 | Application of isoflavone compound in preparation of anti-tumor drug or food |
CN102309479A (en) * | 2011-06-17 | 2012-01-11 | 中国人民解放军第二军医大学 | Application of isoflavone compound in preparation of medicaments or foods for resisting tumors |
CN102718656A (en) * | 2012-06-15 | 2012-10-10 | 济南诚汇双达化工有限公司 | Preparation method of 2-(4-hydroxyphenyl)-propanedioic acidl-[(4-methoxyphenyl)methyl]ester |
CN107118195A (en) * | 2017-06-02 | 2017-09-01 | 云南中烟工业有限责任公司 | A kind of isoflavonoid that can extend the pure tobacco oil shelf-life and preparation method and application |
CN107118195B (en) * | 2017-06-02 | 2019-08-09 | 云南中烟工业有限责任公司 | A kind of isoflavone compound and the preparation method and application thereof that can extend the pure tobacco oil shelf-life |
CN107417611A (en) * | 2017-07-25 | 2017-12-01 | 广州大学 | One kind 3(4 methoxyphenyls)The synthetic method of the bromoquinoline of 6 methoxyl group, 4 chlorine 5,7 2 |
CN107501174A (en) * | 2017-07-25 | 2017-12-22 | 广州大学 | A kind of synthetic method of quinoline |
CN107501175A (en) * | 2017-07-25 | 2017-12-22 | 广州大学 | A kind of synthetic method of quinoline |
CN107522656A (en) * | 2017-07-25 | 2017-12-29 | 南京大学 | One kind 3(4 methoxyphenyls)The synthetic method of the bromoquinoline of 6 methoxyl group, 4 chlorine 5,7 2 |
CN107417612A (en) * | 2017-07-25 | 2017-12-01 | 广州大学 | A kind of synthetic method of quinoline |
CN108685921A (en) * | 2017-12-19 | 2018-10-23 | 广州大学 | A kind of application of the quinoline of N isosteres iridin in medicines resistant to liver cancer |
CN108685921B (en) * | 2017-12-19 | 2020-01-17 | 广州大学 | Application of quinoline derivative of N-isostere tectoridin in anti-liver cancer drugs |
CN108863818A (en) * | 2018-06-28 | 2018-11-23 | 江苏新瑞药业有限公司 | A kind of synthetic method of pair of amino metacresol |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1850817A (en) | Roofirisrhizome flavin non polar isostere, and its preparing method and use | |
CN1096454C (en) | Process for preparing benzofuranone derivatives | |
CN1243000C (en) | Tocopherols, tocotrienols, other chroman and side chain dervative and uses thereof | |
CN1310907C (en) | Heterocyclic compound and antitumour agent containing the same as active ingredient | |
CN1124279C (en) | Platinum complex, its preparation and therapeutic application | |
CN1552711A (en) | Yageine derivative compounds and their uses | |
CN1133642C (en) | Nucleoside 5'-thiophosphoryl amino-acid ester compound | |
CN1481370A (en) | Quinazoline derivatives, medicaments contg. said compounds, their utilization and method for prodn. thereof | |
CN1050182A (en) | Quinone derivatives and medicinal | |
CN1030757A (en) | Benzothiazole derivant | |
CN1340048A (en) | Production of isoflavone derivatives | |
CN1027368C (en) | Process for preparing substituted quinoline derivatives | |
CN1016507B (en) | Forskolin derivatives | |
CN1108657A (en) | Calanthamine derivatives, a process for their preparation and their use as medicaments | |
CN1715283A (en) | Neogambogic acid derivative and its production and use | |
CN1151165A (en) | Triterpene derivative and medicinal composition | |
CN1251836A (en) | Preparation of intermediate for monocyclic beta-lactams derivatives | |
CN1272340C (en) | Oleanolic acid couple derivatives and their pharmaceutical use | |
CN1487934A (en) | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
CN1673228A (en) | Substituted phenoxy acetoxyl aromatic heterocyclic alkyl phosphonate with bactericidal and herbicidal activity and its prepn | |
CN1052865A (en) | New anthracycline class and preparation method thereof | |
CN1057297C (en) | Crystals of antimicrobial compound | |
CN1144586C (en) | 2-(1-hydroxyethyl)-5-hydroxynaphtho{2,3-B}furan-4, 9-dione and antitumor agents comprising this compound | |
CN1086188C (en) | Novel phenanethridinium derivatives | |
CN1741985A (en) | Calcilytic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20061025 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned |